82 related articles for article (PubMed ID: 22133573)
1. Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours?
Walter T; Chardon L; Chopin-laly X; Raverot V; Caffin AG; Chayvialle JA; Scoazec JY; Lombard-Bohas C
Eur J Cancer; 2012 Aug; 48(12):1766-73. PubMed ID: 22133573
[TBL] [Abstract][Full Text] [Related]
2. Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors.
Pulvirenti A; Rao D; Mcintyre CA; Gonen M; Tang LH; Klimstra DS; Fleisher M; Ramanathan LV; Reidy-Lagunes D; Allen PJ
HPB (Oxford); 2019 May; 21(5):612-618. PubMed ID: 30366884
[TBL] [Abstract][Full Text] [Related]
3. Characterization and plasma measurement of the WE-14 peptide in patients with pheochromocytoma.
Guillemot J; Guérin M; Thouënnon E; Montéro-Hadjadje M; Leprince J; Lefebvre H; Klein M; Muresan M; Anouar Y; Yon L
PLoS One; 2014; 9(2):e88698. PubMed ID: 24523932
[TBL] [Abstract][Full Text] [Related]
4. Commentary to "chromogranin a: biological function and clinical utility in neuroendocrine tumor disease".
Jeske W; Glinicki P; Kapuścińska R
Ann Surg Oncol; 2011 Jan; 18(1):293. PubMed ID: 20549561
[No Abstract] [Full Text] [Related]
5. Reply to 'H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines'.
Alvarez MJ; Yan P; Alpaugh ML; Bowden M; Sicinska E; Zhou CW; Karan C; Realubit RB; Mundi PS; Grunn A; Jäger D; Chabot JA; Fojo AT; Oberstein PE; Hibshoosh H; Milsom JW; Kulke MH; Loda M; Chiosis G; Reidy-Lagunes DL; Califano A
Nat Genet; 2019 Oct; 51(10):1427-1428. PubMed ID: 31548719
[No Abstract] [Full Text] [Related]
6. An Overview of Circulating Biomarkers in Neuroendocrine Neoplasms: A Clinical Guide.
Bevere M; Masetto F; Carazzolo ME; Bettega A; Gkountakos A; Scarpa A; Simbolo M
Diagnostics (Basel); 2023 Aug; 13(17):. PubMed ID: 37685358
[TBL] [Abstract][Full Text] [Related]
7. Circulating Neuroendocrine Tumor Biomarkers: Past, Present and Future.
Komarnicki P; Musiałkiewicz J; Stańska A; Maciejewski A; Gut P; Mastorakos G; Ruchała M
J Clin Med; 2022 Sep; 11(19):. PubMed ID: 36233409
[TBL] [Abstract][Full Text] [Related]
8. Plasma protein biomarkers for the detection of pancreatic neuroendocrine tumors and differentiation from small intestinal neuroendocrine tumors.
Thiis-Evensen E; Kjellman M; Knigge U; Gronbaek H; Schalin-Jäntti C; Welin S; Sorbye H; Del Pilar Schneider M; Belusa R;
J Neuroendocrinol; 2022 Jul; 34(7):e13176. PubMed ID: 35829662
[TBL] [Abstract][Full Text] [Related]
9. Laboratory variables as predictors of progression in gastroenteropancreatic neuroendocrine tumors in different lines of antineoplastic treatments.
Armentano DPD; Monteiro MR; Aguiar PN; Tsukamoto JS; Pio RB; Arakelian R; Araujo RLC; Usón Junior PLS
Einstein (Sao Paulo); 2022; 20():eAO6985. PubMed ID: 35674592
[TBL] [Abstract][Full Text] [Related]
10. Perspectives on the diagnostic, predictive and prognostic markers of neuroendocrine neoplasms (Review).
Ciobanu OA; Martin S; Fica S
Exp Ther Med; 2021 Dec; 22(6):1479. PubMed ID: 34765020
[TBL] [Abstract][Full Text] [Related]
11. Significance of chromogranin A and synaptophysin in medullary thyroid carcinoma.
Tomita T
Bosn J Basic Med Sci; 2021 Oct; 21(5):535-541. PubMed ID: 33485291
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management-An Updated Review.
Bocchini M; Nicolini F; Severi S; Bongiovanni A; Ibrahim T; Simonetti G; Grassi I; Mazza M
Front Oncol; 2020; 10():831. PubMed ID: 32537434
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management.
Ma ZY; Gong YF; Zhuang HK; Zhou ZX; Huang SZ; Zou YP; Huang BW; Sun ZH; Zhang CZ; Tang YQ; Hou BH
World J Gastroenterol; 2020 May; 26(19):2305-2322. PubMed ID: 32476795
[TBL] [Abstract][Full Text] [Related]
14. Significance of chromogranin A and synaptophysin in pancreatic neuroendocrine tumors.
Tomita T
Bosn J Basic Med Sci; 2020 Aug; 20(3):336-346. PubMed ID: 32020844
[TBL] [Abstract][Full Text] [Related]
15. Specific and Non-Specific Biomarkers in Neuroendocrine Gastroenteropancreatic Tumors.
Sansone A; Lauretta R; Vottari S; Chiefari A; Barnabei A; Romanelli F; Appetecchia M
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31382663
[TBL] [Abstract][Full Text] [Related]
16. Low accuracy of chromogranin A for diagnosing early-stage pancreatic neuroendocrine tumors.
Tseng CM; Cheng TY; Chen TB; Tien YW; Chen CC; Lin JT; Wang HP
Oncol Lett; 2018 Jun; 15(6):8951-8958. PubMed ID: 29805630
[TBL] [Abstract][Full Text] [Related]
17. Hormone secreting gastro-entero-pancreatic neuroendocrine neoplasias (GEP-NEN): When to consider, how to diagnose?
Fottner C; Ferrata M; Weber MM
Rev Endocr Metab Disord; 2017 Dec; 18(4):393-410. PubMed ID: 29256148
[TBL] [Abstract][Full Text] [Related]
18. Neutrophil-lymphocyte ratio predicts survival in pancreatic neuroendocrine tumors.
Luo G; Liu C; Cheng H; Jin K; Guo M; Lu Y; Long J; Xu J; Ni Q; Chen J; Yu X
Oncol Lett; 2017 Apr; 13(4):2454-2458. PubMed ID: 28454419
[TBL] [Abstract][Full Text] [Related]
19. Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients.
Qiu W; Christakis I; Silva A; Bassett RL; Cao L; Meng QH; Gardner Grubbs E; Zhao H; Yao JC; Lee JE; Perrier ND
Clin Endocrinol (Oxf); 2016 Sep; 85(3):400-7. PubMed ID: 27256431
[TBL] [Abstract][Full Text] [Related]
20. Circulating Chromogranin A as A Marker for Monitoring Clinical Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors.
Tian T; Gao J; Li N; Li Y; Lu M; Li Z; Lu Z; Li J; Shen L
PLoS One; 2016; 11(5):e0154679. PubMed ID: 27159453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
